down arrow

Zimmer Biomet Holdings, Inc.

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US98956P1021
USD
93.16
0.06 (0.06%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

92.1793.25

52 Week

85.34114.44
Valuation
Technical
Day's Volume

CASH

594.15 k

Shareholding (Mar 2025)

FII

16.04%

Held by 379 FIIs

DII

27.27%

Held by 80 DIIs

Promoter

0.14%

How big is Zimmer Biomet Holdings, Inc.?

22-Jun-2025

As of Jun 18, Zimmer Biomet Holdings, Inc. has a market capitalization of $27.21 billion, with net sales of $7.70 billion and a net profit of $914.90 million over the latest four quarters.

Market Cap: As of Jun 18, Zimmer Biomet Holdings, Inc. has a market capitalization of 27,211.66 million, classifying it as a Large Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Zimmer Biomet reported net sales of 7,698.50 million and a net profit of 914.90 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 12,468.10 million and total assets of 21,365.30 million.

Read More

What does Zimmer Biomet Holdings, Inc. do?

22-Jun-2025

Zimmer Biomet Holdings, Inc. designs, manufactures, and markets orthopedic reconstructive products and surgical solutions. As of March 2025, it reported net sales of $1.909 billion and a market cap of approximately $27.21 billion.

Overview:<BR>Zimmer Biomet Holdings, Inc. is engaged in designing, manufacturing, and marketing orthopedic reconstructive products and related surgical solutions within the Pharmaceuticals & Biotechnology industry, classified as a large-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 1,909 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 183 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 27,211.66 Million (Large Cap)<BR><BR>Key Metrics:<BR>P/E: 25.00 <BR>Dividend Yield: 73.72% <BR>Debt Equity: 0.47 <BR>Return on Equity: 8.93% <BR>Price to Book: 2.20 <BR><BR>Contact Details:<BR>Address: 345 E Main St, WARSAW IN: 46580-2746 <BR>Tel: 1 574 2676131 <BR>Website: http://www.zimmerbiomet.com/

Read More

Who are in the management team of Zimmer Biomet Holdings, Inc.?

22-Jun-2025

As of March 2022, the management team of Zimmer Biomet Holdings, Inc. includes Mr. Larry Glasscock (Independent Non-Executive Chairman), Mr. Bryan Hanson (President and CEO), and several Independent Directors: Mr. Christopher Begley, Ms. Betsy Bernard, Ms. Gail Boudreaux, and Mr. Michael Farrell. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Zimmer Biomet Holdings, Inc. includes the following individuals:<BR><BR>- Mr. Larry Glasscock, Independent Non-Executive Chairman of the Board<BR>- Mr. Bryan Hanson, President, Chief Executive Officer, Director<BR>- Mr. Christopher Begley, Independent Director<BR>- Ms. Betsy Bernard, Independent Director<BR>- Ms. Gail Boudreaux, Independent Director<BR>- Mr. Michael Farrell, Independent Director<BR><BR>This team is responsible for overseeing the company's strategic direction and operations.

Read More

Is Zimmer Biomet Holdings, Inc. technically bullish or bearish?

14-Oct-2025

As of October 10, 2025, Zimmer Biomet Holdings, Inc. shows a neutral trend with mixed indicators, underperforming the S&P 500 year-to-date at -9.98% compared to 11.41%.

As of 10 October 2025, the technical trend for Zimmer Biomet Holdings, Inc. has changed from mildly bearish to sideways. The current stance is neutral, with mixed indicators influencing the outlook. The weekly MACD and Bollinger Bands are bearish, while the daily moving averages show a mildly bullish signal. The KST is bullish on a weekly basis but bearish monthly, and Dow Theory indicates a mildly bearish weekly trend alongside a mildly bullish monthly trend. <BR><BR>In terms of performance, Zimmer Biomet has underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -9.98% versus the S&P 500's 11.41%, and a 5-year return of -32.31% compared to the S&P 500's 88.45%.

Read More

Is Zimmer Biomet Holdings, Inc. overvalued or undervalued?

05-Nov-2025

As of October 31, 2025, Zimmer Biomet Holdings, Inc. is fairly valued with a P/E ratio of 25, but has underperformed the S&P 500 with a year-to-date return of -2.32% and a five-year decline of 22.03%.

As of 31 October 2025, the valuation grade for Zimmer Biomet Holdings, Inc. moved from expensive to fair. Based on the current metrics, the company appears to be fairly valued. Key ratios include a P/E ratio of 25, an EV to EBITDA of 13.72, and a Price to Book Value of 2.25. In comparison to peers, Agilent Technologies, Inc. has a P/E of 27.42, while GE Healthcare Technologies, Inc. stands out with a much lower P/E of 15.07, indicating that Zimmer Biomet is positioned competitively within its industry.<BR><BR>Despite the fair valuation, Zimmer Biomet has underperformed relative to the S&P 500, with a year-to-date return of -2.32% compared to the index's 16.30%. Over the past five years, the company has seen a decline of 22.03%, while the S&P 500 has gained 109.18%, further emphasizing the challenges the company faces in generating shareholder value.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor long term growth as Net Sales has grown by an annual rate of 2.19% and Operating profit at 14.17% over the last 5 years

 
2

Negative results in Jun 25

3

With ROCE of 7.93%, it has a fair valuation with a 1.85 Enterprise value to Capital Employed

4

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 31,612 Million (Mid Cap)

stock-summary
P/E

25.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

47.75%

stock-summary
Debt Equity

0.56

stock-summary
Return on Equity

8.51%

stock-summary
Price to Book

2.52

Revenue and Profits:
Net Sales:
2,077 Million
(Quarterly Results - Jun 2025)
Net Profit:
153 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-11.07%
0%
-11.07%
6 Months
1.86%
0%
1.86%
1 Year
-15.78%
0%
-15.78%
2 Years
-20.3%
0%
-20.3%
3 Years
-24.24%
0%
-24.24%
4 Years
-20.78%
0%
-20.78%
5 Years
-35.57%
0%
-35.57%

Zimmer Biomet Holdings, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Zimmer Biomet Hits Day Low of $85.84 Amid Price Pressure

Zimmer Biomet Hits Day Low of $85.84 Amid Price Pressure

Zimmer Biomet Holdings, Inc. has faced notable stock volatility, with significant declines over various time frames, including a year-to-date drop of 17.12%. Financial challenges are evident, including a 28.26% decrease in net profit and a high debt-equity ratio, although institutional ownership remains strong at 99.22%.

Read More

Is Zimmer Biomet Holdings, Inc. overvalued or undervalued?

As of 31 October 2025, the valuation grade for Zimmer Biomet Holdings, Inc. moved from expensive to fair. Based on the current metrics, the company appears to be fairly valued. Key ratios include a P/E ratio of 25, an EV to EBITDA of 13.72, and a Price to Book Value of 2.25. In comparison to peers, Agilent Technologies, Inc. has a P/E of 27.42, while GE Healthcare Technologies, Inc. stands out with a much lower P/E of 15.07, indicating that Zimmer Biomet is positioned competitively within its industry. Despite the fair valuation, Zimmer Biomet has underperformed relative to the S&P 500, with a year-to-date return of -2.32% compared to the index's 16.30%. Over the past five years, the company has seen a decline of 22.03%, while the S&P 500 has gained 109.18%, further emphasizing the challenges the company faces in generating shareholder value....

Read More

Is Zimmer Biomet Holdings, Inc. overvalued or undervalued?

As of 31 October 2025, the valuation grade for Zimmer Biomet Holdings, Inc. moved from expensive to fair. The company appears fairly valued based on its current metrics, with a P/E ratio of 25, a Price to Book Value of 2.25, and an EV to EBITDA of 13.72. In comparison to peers, Edwards Lifesciences Corp. has a higher P/E of 31.17, while GE Healthcare Technologies, Inc. shows a more attractive valuation with an EV to EBITDA of 12.18. Despite the fair valuation, Zimmer Biomet has underperformed relative to the S&P 500, with a year-to-date return of -5.44% compared to the S&P 500's 16.30%. This underperformance over multiple periods, including a 5-year return of -24.52% versus the S&P 500's 109.18%, suggests that while the stock is fairly valued, it may face challenges in regaining investor confidence....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
2.19%
EBIT Growth (5y)
14.17%
EBIT to Interest (avg)
6.38
Debt to EBITDA (avg)
2.71
Net Debt to Equity (avg)
0.47
Sales to Capital Employed (avg)
0.40
Tax Ratio
12.92%
Dividend Payout Ratio
21.66%
Pledged Shares
0
Institutional Holding
99.22%
ROCE (avg)
6.76%
ROE (avg)
8.16%
Valuation key factors
Factor
Value
P/E Ratio
25
Industry P/E
Price to Book Value
2.25
EV to EBIT
23.35
EV to EBITDA
13.72
EV to Capital Employed
1.85
EV to Sales
4.37
PEG Ratio
NA
Dividend Yield
71.99%
ROCE (Latest)
7.93%
ROE (Latest)
8.93%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 174 Schemes (56.32%)

Foreign Institutions

Held by 379 Foreign Institutions (16.04%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 6.97% vs 3.87% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -36.90% vs 15.82% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,077.30",
          "val2": "1,942.00",
          "chgp": "6.97%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "659.30",
          "val2": "622.80",
          "chgp": "5.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "75.80",
          "val2": "50.90",
          "chgp": "48.92%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-115.30",
          "val2": "-37.20",
          "chgp": "-209.95%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "153.40",
          "val2": "243.10",
          "chgp": "-36.90%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "186.50%",
          "val2": "195.50%",
          "chgp": "-0.90%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 3.85% vs 6.55% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -11.70% vs 252.03% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "7,678.60",
          "val2": "7,394.20",
          "chgp": "3.85%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "2,481.30",
          "val2": "2,338.70",
          "chgp": "6.10%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "207.10",
          "val2": "195.30",
          "chgp": "6.04%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-326.40",
          "val2": "-201.70",
          "chgp": "-61.82%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "905.20",
          "val2": "1,025.10",
          "chgp": "-11.70%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "193.40%",
          "val2": "187.60%",
          "chgp": "0.58%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
2,077.30
1,942.00
6.97%
Operating Profit (PBDIT) excl Other Income
659.30
622.80
5.86%
Interest
75.80
50.90
48.92%
Exceptional Items
-115.30
-37.20
-209.95%
Consolidate Net Profit
153.40
243.10
-36.90%
Operating Profit Margin (Excl OI)
186.50%
195.50%
-0.90%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 6.97% vs 3.87% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -36.90% vs 15.82% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
7,678.60
7,394.20
3.85%
Operating Profit (PBDIT) excl Other Income
2,481.30
2,338.70
6.10%
Interest
207.10
195.30
6.04%
Exceptional Items
-326.40
-201.70
-61.82%
Consolidate Net Profit
905.20
1,025.10
-11.70%
Operating Profit Margin (Excl OI)
193.40%
187.60%
0.58%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 3.85% vs 6.55% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -11.70% vs 252.03% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Zimmer Biomet Holdings, Inc. stock-summary
stock-summary
Zimmer Biomet Holdings, Inc.
Pharmaceuticals & Biotechnology
Zimmer Biomet Holdings, Inc. is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The Company's products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. The Company manages its operations through three geographic operating segments: the Americas, consisting principally of the United States and other North, Central and South American markets; EMEA, consisting principally of Europe and the Middle East and African markets, and Asia Pacific, consisting primarily of Japan and other Asian and Pacific markets. The Company's product category segments include Americas Spine, Office Based Technologies, Craniomaxillofacial and Thoracic (CMF), and Dental.
Company Coordinates stock-summary
Company Details
345 E Main St , WARSAW IN : 46580-2746
stock-summary
Tel: 1 574 2676131
stock-summary
http://www.zimmerbiomet.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."